Conceivable Life Sciences

C:EGG uses full-depth imaging and OCT to detect oocytes that conventional microscopy misses, especially in cloudy or blood-tinged follicular fluid.

SiD provides objective motility data for embryologist-led sperm selection for ICSI. Four independent studies showed improved blastocyst formation, especially for older patients.

The page presents insights on IVF innovation, automation, and the future of fertility care from Conceivable Life Sciences and industry leaders.

C:SPERM, part of AURA, uses centrifuge-free sperm preparation to protect DNA integrity before injection and select healthier sperm.

Joshua Abram & Alan Murray are serial entrepreneurs and Co-Founders of Conceivable, driving innovation in fertility tech with expertise and scaling ventures.

Dr. Alejandro Chavez-Badiola is Co-Founder & Chief Medical Officer at Conceivable, bringing clinical leadership to scale reproductive health globally.

Brian Bixon is SVP of Product, leading the development of AI‑powered IVF automation systems with a focus on precision, scalability, and operational excellence.

Dr. Jacques Cohen is a pioneering embryologist and ART innovator whose decades of leadership in IVF science power breakthroughs in fertility automation.

The page describes Conceivable Life Sciences' mission, vision, founding team, and use of automation and AI in fertility care.

Conceivable Life Sciences accepts press inquiries through its contact form or email and has offices in New York, London, and Guadalajara.

Conceivable Life Sciences: pioneering the world’s first AI-powered automated IVF lab (AURA) to lower cost, increase access, and improve fertility outcomes.”

Conceivable Life Sciences' Privacy Policy describes how the company collects, uses, and protects personal information when people access its website and services.

Conceivable's Terms of Service outline the terms for accessing and using its website and services, including its AI-powered IVF automation technology.

UCSF partners with Conceivable Life Sciences to develop an IVF laboratory automation research center. The initiative integrates UCSF’s clinical expertise with Conceivable’s **AURA platform**, an AI-assisted automation system for in-vitro fertilization labs. The system operates under embryologist supervision and leverages **Physical AI** for workflow optimization.

Oct 2026Today's Clinical LabNews article

IVI RMA Global partners with Conceivable Life Sciences to deploy the first automated in vitro fertilization (IVF) lab in the United States. The collaboration integrates advanced automation technology into fertility treatments, aiming to enhance efficiency and patient outcomes. Both companies leverage IVI RMA Global’s clinical expertise and Conceivable’s automated lab systems to streamline IVF processes.

Jul 2026Yahoo FinanceNews article

Conceivable Life Sciences secures $50 million in Series A funding to deploy its AI-powered, automated in vitro fertilization (IVF) lab platform across the US. The round, led by Advance Venture Partners, elevates the company’s total funding to $70 million, with support from returning investors ARTIS Ventures, Stride, and ACME. The platform aims to streamline IVF processes through automation and artificial intelligence.

Sep 2025Women's TabloidNews article

Conceivable Life Sciences secures $50 million in Series A funding to develop automated in vitro fertilization (IVF) laboratories. The company aims to streamline reproductive healthcare through automation. CEO Alan Murray leads the initiative, focusing on efficiency in IVF processes.

Sep 2025AxiosNews article